Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine as adjunctive treatment in schizophrenia
NCT05110157Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2021
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Placebo Arm with Valbenazine Arm (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 10 weeks. Started Nov 2021; status: completed.
02
Drugs
valbenazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05110157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110157.